IP Library Granted Patent US 7,625,907
Granted Patent B2
US 7,625,907 · App. 11/430,986 · Granted Dec 1, 2009

Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof

Assignees: Duke University; Johns Hopkins University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,625,907
App. No.
11/430,986
Granted
Dec 1, 2009
Kind
B2
Abstract

A reactive oxygen generating enzyme inhibitor with NO donor bioactivity, e.g., nitrated allopurinol, is useful to treat heart failure, stable angina, ischemic disorder, ischemic reperfusion injury, atherosclerosis, sickle cell disease, diabetes, Alzheimer's disease, Parkinson's disease, ALS and asthma and to obtain proper contraction of heart, skeletal and smooth muscle.

Claims (3)

1. A method of treating a patient with a disorder associated with oxidative stress which is ischemic reperfusion injury, comprising administering to that patient a therapeutically effective amount of 1,5-bis(3-nitrooxypropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one.

2. The method of claim 1 where the administration is in an amount to mediate amelioration of symptoms of pain, organ damage and/or arrythmia.

3. The method of claim 1 where the 1,5-bis(3-nitrooxypropyl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one is administered orally on a daily basis in an amount ranging from 100 to 800 mg/day.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jan 19, 2022
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 058696/0650 →
Continuity (2)
Continuation 1082994000 · Apr 23, 2004
Related Publication 20060194820A1 · Aug 31, 2006